Applied DNA Regains Compliance With Nasdaq Minimum Bid Price Requirement
Applied DNA Regains Compliance With Nasdaq Minimum Bid Price Requirement
STONY BROOK, NY / ACCESSWIRE / September 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that on September 17, 2024, it received a notification letter (the "Notification Letter") from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq"), informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement").
紐約-2024年9月18日-應用DNA科學公司（納斯達克：APDN）（Applied DNA），一家PCR基因技術領軍企業，今天宣佈，在2024年9月17日收到來自納斯達克交易所上市資格部門（納斯達克）的通知函（「通知函」），通知公司已恢復符合納斯達克上市規則5550（a）（2）中規定的最低買盤價格要求（「最低買盤價要求」）。
As previously reported, the Company was notified on July 12, 2024, that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Minimum Bid Price Requirement. To regain compliance with the Minimum Bid Price Requirement, the closing bid of the Company's common stock needed to be at least $1.00 for a minimum of 10 consecutive business days (the "Compliance Period"), with said Compliance Period extendable generally not to exceed 20 consecutive business days pursuant to Nasdaq Listing Rule 5810(c)(3)(H).
正如先前報道的那樣，該公司於2024年7月12日收到通知，其普通股未能維持每股最低$1.00的要求，此要求需在最近30個連續的營業日內符合最低買盤價格要求。爲了重新符合最低買盤價格要求，公司普通股的收盤買盤價格需要至少爲每股$1.00，持續至少10個連續營業日（「符合期」），通常可根據納斯達克上市規則5810（c）（3）（H）延長，但總體不超過20個連續營業日。
On September 17, 2024, Nasdaq determined that for the last 20 consecutive business days, from August 19 through September 16, 2024, the closing bid price of the Company's common stock was $1.00 per share or greater. Accordingly, the Company has regained compliance with the Minimum Bid Price Requirement, and Nasdaq considers this matter now closed.
在2024年9月17日，納斯達克確定，在過去的20個連續營業日，即從2024年8月19日至9月16日期間，公司普通股的收盤買盤價格爲每股$1.00或更高。因此，公司已恢復符合最低買盤價格要求，而納斯達克認爲此事已經解決。
About Applied DNA Sciences
Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in three primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.
關於Applied DNA Sciences
應用DNA科學是一家生物技術公司，開發產生和檢測脫氧核糖核酸（"DNA")的技術。通過聚合酶鏈反應（"PCR")實現DNA的產生和檢測，我們在三個主要的業務市場運營：（i）酶法合成DNA用於核酸治療藥物的生產，以及開發和銷售專有RNA聚合酶（"RNAP")的mRNA治療藥物的生產；（ii）分子診斷和基因檢測服務中的DNA和RNA檢測；（iii）用於工業供應鏈安全服務的DNA的製造和檢測。
Visit adnas.com for more information. Follow us on X and LinkedIn. Join our mailing list.
請訪問adnas.com了解更多信息。關注我們的X和領英。加入我們的郵件列表。
Forward-Looking Statements
The statements made by Applied DNA in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, the substantial doubt about its ability to continue as a going concern, the unknown future ability to meet all Nasdaq listing requirements, the unknown future demand for its biotherapeutics products and services, the unknown amount of revenues and profits that will result from our Linea IVT and or Linea DNA platforms, limited market acceptance for its supply chain security products and services, the fact that there has never been a commercial drug product utilizing PCR-produced DNA technology and/or the Linea IVT platform approved for therapeutic use, and various other factors detailed from time to time in Applied DNA's SEC reports and filings, including its Annual Report on Form 10-K, as amended, filed on December 7, 2023, Quarterly Reports on Form 10-Q filed on February 8, 2024, May 10, 2024, and August 8, 2024, and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
前瞻性聲明
applied dna公司在本新聞稿中所作的陳述可能具有「前瞻性」性質，屬於1933年證券法第27(a)條，1934年證券交易法第21(e)條和1995年私人證券訴訟改革法的適用範圍。前瞻性陳述描述了applied dna的未來計劃、預測、策略和期望，並基於一系列假設，涉及多種風險和不確定性，其中許多超出了applied dna的控制範圍。由於applied dna的歷史淨虧損、有限的財務資源、無法確定能否繼續作爲經營實體的重大質疑、無法確定能否滿足所有納斯達克上市要求的未來能力、其生物治療產品和服務的未來需求未知、我們的Linea IVt和/或Linea dna平台將獲得的收入和利潤的未知量、對其供應鏈安全產品和服務市場認可度有限、尚未有經PCR製造的DNA技術和/或Linea IVt平台獲得治療用途批准的商業藥物產品、以及其他因素，applied dna的實際結果可能與預計結果存在重大差異，這些因素將從時間到時間詳細列入applied dna的SEC報告和文件中，其中包括其2023年12月7日修訂的年度報告Form 10-k，2024年2月8日、5月10日和8月8日提交的季度報告Form 10-Q，以及其他提交給SEC的報告，這些報告可在www.sec.gov上獲得。applied dna不承諾公開更新任何前瞻性陳述，以反映新信息、事件或情況的發生，除非法律另有要求。
Contacts:
Applied DNA Sciences
Investor Relations contact: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com
Web:
X: @APDN
聯繫人：
Applied DNA Sciences
投資者關係聯繫人：Sanjay M. Hurry，917-733-5573，sanjay.hurry@adnas.com
網站：
X：@APDN
SOURCE: Applied DNA Sciences
來源：applied dna sciences
譯文內容由第三人軟體翻譯。